Table 7_Serotonin syndrome risk with concomitant opioid and serotonergic antidepressant us

A 10.3 KB pharmacovigilance dataset by Junge Zhang, last updated March 2026, analyzes adverse event reports from the US FDA FAERS and Japanese JADER databases from Q1 2004 to Q2 2025. It quantifies the risk of serotonin syndrome and other adverse events from concomitant opioid and serotonergic antidepressant use using disproportionality analyses.

Use Cases

• Quantifying serotonin syndrome risk signals based on Reporting Odds Ratios (ROR) for specific drug combinations.
• Analyzing gender-stratified reporting patterns for adverse events mentioned in the study results.
• Investigating time-to-onset profiles for adverse events, including long-term risks beyond 300 days.
• Comparing adverse event profiles (e.g., cardiac disorders, withdrawal syndrome) between SSRI-opioid and SNRI-opioid combinations.

Strengths

• Multinational data coverage from US and Japanese pharmacovigilance databases.
• Specific risk metrics provided, including ROR 95.94 for SSRI-opioid serotonin syndrome risk.
• Time range spans over two decades, from Q1 2004 to Q2 2025.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect reporting bias inherent to pharmacovigilance systems.

Provenance

Source

US FDA Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report database (JADER).

Collection Method

Disproportionality analyses, including Reporting Odds Ratio (ROR) with a multi-algorithm framework.

Time Range

Q1 2004 to Q2 2025.

Freshness

Last updated 2026-03-18 08:44:19; freshness should be verified.

Geography

Multinational (United States and Japan).